At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
exendin 9-39 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
In Brief
A Phase 2 clinical trial evaluating exendin 9-39 and Placebo for Postbariatric Hypoglycemia. Completed, enrolled 18 participants across 5 sites.
Detailed Summary
This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostbariatric Hypoglycemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartMar 2018
Primary CompletionJan 2019
Study CompletionMar 2019
TodayJul 2026
First PostedDec 14, 2017
Enrollment StartMar 19, 2018
Primary CompletionJan 30, 2019
Study CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.5 years ago
Interventions
exendin 9-39drug
Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
Placeboother
Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.